Third Circuit overturns pay-for-delay dismissals

Plaintiffs need not calculate likely damages to be obtained from patent litigation - nor various other factors - to plausibly allege that a pharmaceutical company cut a deal with a would-be generic competitor that violates antitrust law, a federal appellate court has held.

Unlock unlimited access to all Global Competition Review content